ERHS 551B - Radiation Biology Principles for Medicine: Principles of Radiation Oncology

  • 2 credits

Application of basic radiation biology to the clinical application of radiation therapy. Radiation sensitivity and tolerance is evaluated based on normal tissue architecture and kinetics. The mechanisms of acute and late radiation effects are elucidated. The impact of time, dose, and fractionation on tumor control and radiation effects are clarified and related to established and newer treatment modalities, including combination therapies and emerging technologies.

This course requires the use of electronic proctoring through ProctorU, please see http://www.online.colostate.edu/current-students/proctoring.dot for detailed instructions.  For students requiring accommodations, please contact Resources for Disabled Students (RDS); for consideration of exceptions outside the scope of RDS, please contact the University Testing Center.

Prerequisite

ERHS 551A (Radiation Biology Principles for Medicine: Principles of Radiation Biology). Credit not allowed for both ERHS 551B and ERHS 550 (Principles of Radiation Biology).

Important Information

This course is also available as a noncredit option. See the EDLL 2008 course page if you want the content, but don't need the college credits.

Textbooks and Materials

Textbooks and materials can be purchased at the CSU Bookstore unless otherwise indicated.

Required

  • Radiobiology for the Radiologist, 7th Ed. (2012)
    Hall, Eric J. and Giaccia, Amato J.

Instructors

Susan LaRue

(970) 297-0334 | susan.larue@colostate.edu

Dr. LaRue is Professor of Cancer Radiotherapy. Dr. LaRue’s translational research employs naturally occurring tumors in companion animals to develop new combination radiotherapy protocols and better understand the biology of the cancer. Understanding the mechanisms of radiation-induced tissue damage as a by-product of radiation therapy is a primary interest. Dr. LaRue is currently working on a project to develop a model of radiation-induced erectile dysfunction, and evaluating radiation protocols that might mitigate non-target tissue damage in radiation oncology therapies of the prostate.

Loading...